- Home
- FOLD vs DXC Comparison
FOLD vs DXC Comparison
Compare FOLD & DXC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- FOLD
- DXC
- Stock Information
- Founded
- FOLD 2002
- DXC 1959
- Country
- FOLD United States
- DXC United States
- Employees
- FOLD 499
- DXC N/A
- Industry
- FOLD Biotechnology: Pharmaceutical Preparations
- DXC EDP Services
- Sector
- FOLD Health Care
- DXC Technology
- Exchange
- FOLD Nasdaq
- DXC Nasdaq
- Market Cap
- FOLD 2.5B
- DXC 2.6B
- IPO Year
- FOLD 2007
- DXC N/A
- Fundamental
- Price
- FOLD $8.42
- DXC $13.01
- Analyst Decision
- FOLD Strong Buy
- DXC Hold
- Analyst Count
- FOLD 9
- DXC 6
- Target Price
- FOLD $26.44
- DXC $15.60
- AVG Volume (30 Days)
- FOLD 5.3M
- DXC 1.8M
- Earning Date
- FOLD 11-05-2025
- DXC 10-30-2025
- Dividend Yield
- FOLD N/A
- DXC N/A
- EPS Growth
- FOLD N/A
- DXC 384.35
- EPS
- FOLD N/A
- DXC 2.05
- Revenue
- FOLD $571,160,000.00
- DXC $12,794,000,000.00
- Revenue This Year
- FOLD $21.04
- DXC N/A
- Revenue Next Year
- FOLD $21.34
- DXC N/A
- P/E Ratio
- FOLD N/A
- DXC $6.28
- Revenue Growth
- FOLD 25.35
- DXC N/A
- 52 Week Low
- FOLD $5.51
- DXC $12.24
- 52 Week High
- FOLD $12.65
- DXC $24.83
- Technical
- Relative Strength Index (RSI)
- FOLD 57.84
- DXC 43.06
- Support Level
- FOLD $7.87
- DXC $12.63
- Resistance Level
- FOLD $8.49
- DXC $13.50
- Average True Range (ATR)
- FOLD 0.37
- DXC 0.40
- MACD
- FOLD -0.03
- DXC -0.05
- Stochastic Oscillator
- FOLD 81.67
- DXC 27.54
About FOLD Amicus Therapeutics Inc.
Amicus Therapeutics Inc is a patient-dedicated biotechnology company focused on discovering, developing and delivering novel high-quality medicines for people living with rare diseases. With extraordinary patient focus, the company is committed to advancing and expanding a pipeline of cutting-edge medicines for rare diseases. It has a portfolio of product opportunities, including oral precision medicine for people living with Fabry disease who have amenable genetic variants; a clinical-stage, treatment paradigm for Pompe disease, and a rare disease gene therapy portfolio. The company has one segment focused on the discovery, development, and commercialization of therapies to treat a range of devastating rare and orphan diseases.
About DXC DXC Technology Company
DXC Technology Co is a vendor-independent IT services provider. The company's operating segment includes Global Business Services (GBS) and Global Infrastructure Services (GIS). It generates maximum revenue from the GIS segment. GIS offerings include Cloud and Security; IT Outsourcing and Modern Workplace. Geographically, it derives a majority of revenue from the Other Europe region.